Information for Healthcare Professionals on the Supply of Chiesi Products
Updated: 14th October 2020
We continue to work closely with all stakeholders involved in responding to the unprecedented increase in demand as best and as efficiently as possible. This includes working hard to manage supply, consistently releasing stock weekly at average demand levels to supply the wholesalers. We expect continued stock deliveries over the coming weeks and months. We can also confirm that production of all our respiratory products, including Clenil® Modulite® (beclometasone), Fostair® (beclometasone/ formoterol) and Trimbow® (beclometasone/ formoterol/ glycopyrronium), continues uninterrupted at all of our manufacturing sites.
Clenil® Modulite® 100mcg (beclometasone): release of batch specific variation
To address the current increased demand of Clenil Modulite 100mcg (beclometasone), additional batches have been released into the UK supply chain following authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for a batch-specific variation.
The numbers of the batches authorised by the MHRA so far are 1112190, 1112214 to 1112219 and 1900001 to 1900070.
Further batches of the Clenil 100mcg batch specific variation will be released into the supply chain over the coming months, which will continue to address the increase in demand. This website will be updated regularly to inform you of the additional batches that will be released.
Summary of key information related to batch variation:
If dispensing this product, healthcare professionals should:
Additional information to share with your patients who have received a batch-specific variation Clenil 100mcg can be downloaded here.
We repeat our appeal to all healthcare professionals involved in prescribing and dispensing our range of products to help us maintain supply by continuing to write monthly repeat prescriptions rather than prescriptions for multiple months’ supply of inhalers until such time as the short-term pressures begin to ease. This will help us immensely in being able to continue to supply all our products to all our patients during this time by bringing demand in line with supply.
Please do not hesitate to contact the Customer Services team via email (CustomerServices.UK@chiesi.com) should you have any further questions or require additional information.
UK-CLE-2000061 October 2020